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New Breast Cancer
VOL. 44, NO. 6
Prevention Trial
TI-E l.NNERSilY OF TEXAS In a new study of postMDANJERSON menopausal women,
CANCER CENTER raloxifene squares off
Making Cancer History™ against tamoxifen.

•.· pass
Quarterly Supplement
Compass brings you
a prostate cancer
guideline plus a Q&A
with its developers.
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Patient Education:
Cancer Screening
Share this cancer
screening checklist
with patients to promote early detection.

6

life After
Prostatedomy
Surgeons employ
sural nerve graft in
attempt to restore
erectile function.

MD Anderson

After Diagnosis, Another Hurdle:
Cancer Screening for the Cancer Patient
by Jude Richard

cared, mystified, sometimes
both-that's how Therese
Bevers, M.D., medical director
of the Cancer Prevention Center
( CPC) at The University of
Texas M. D. Anderson Cancer
Center, says many cancer
patients feel when they first
come for cancer screening.

" ... the patient is more
susceptible to other cancers
and other illnesses:'
- Mervianna Thompson, R.N., C.S.,
A.N.P., A.O.C.N., nurse practitioner,
Cancer Prevention Center

"The occasional patient is so
shocked already by the diagnosis
of his or her first primary cancer,"
says nurse practitioner Mervianna
Thompson, RN., C.S., A.N.P.,
A.O.C.N., who screens patients
in the CPC daily, "that they can't
handle screening and the possibility
that another cancer will be found."
But when they leave-after they
understand screening's benefitsthey're often thinking differently.
"The cancer patient must be
reminded," advises Lewis Foxhall,
M.D., "that having one cancer may
make it more likely he'll have a
(Continued on next page)

"More and more patients
are also asking for
genetic screening:'
- Therese Bevers, M.D.,
medical director,
Cancer Prevention Center

Cancer.Screening
(Continued from page 1)

second primary and that, consequently, the patient needs to stay
healthy and have recommended
regular screening." Dr. Foxhall,
who formerly referred patients to
M. D. Anderson from a primary
care practice, now is co-medical
director of M. D. Anderson's Office
of Referral Relations.
Educating the patient is part of
the process, Thompson agrees. "We
first explain we're looking for other
cancers before they become more
advanced, which requires more
extensive treatment."
The patients' own experience
with early detection of a primary
cancer can make the search for
second primaries palatable, according to Dr. Bevers. "Often, when we
establish that a patient has a good
chance of survival because the cancer
was caught early, we use that example
to convince the patient of the need
for continued screening," she said.
Furthermore, patients aren't the
only ones unsure about screening in
cancer patients. Members of the
American Society of Clinical Oncology said in a survey reported in 1992
that lack of patients in their practice
without cancer and the difficulty of
incorporating screening economically into practice were major barriers to putting cancer screening and
prevention activities into practice.
or the best patient
outcome, primary physician, oncologist, and
patient must cooperate
in screening efforts. If
not performed by the oncologist
during workup, screening may be
done by the community physician
if indicated based on the projected
outcome of the cancer treatment.
"Communication between the
oncologist and the community
physician is key since the community
physician often keeps seeing the
patient while the patient is being
treated over time for the cancer,"
says Dr. Foxhall.
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Treatment, too, is shifting after
diagnosis at major centers like M. D.
Anderson to treatment near home.
"Occasionally, recommended treatment is being done in the community, after centers like ours have
done the initial screening and
workup," said Thompson. "The
community physician is then more
involved in screening the patient
on a regular basis and sends the
patient back to the oncologist for
regular checkups."
When the community physician
will be performing the screening,
Dr. Bevers said the oncologist must
make clear to the community physician the outlook for the patient,
including "the exact ramifications
of the patient's tumor stage and
grade, treatment, treatment-related
side effects, and expected five-year
survival and recurrence rates."
"Certain cancers have certain
life expectancies, and at some point,
screening for other life-threatening
conditions may no longer be of
benefit to the patient," she said.
"But until that point, the patient
should continue being screened."
Once determined necessary,
however, screening should be
regular.
"Wherever the screening is
done and whoever does it, vigilance
must increase," according to Dr.
Foxhall.
"What cancer patient, oncologist,
and community physician must all
remember is that the patient is
more susceptible to other cancers
and other illnesses and that concerted primary surveillance and
secondary screening is necessary,"
said Thompson.
Dr. Foxhall said that in his experience, patients often became more
willing to be regularly screened after
they have had a cancer diagnosed:
"The diagnosis of that first primary
cancer breaks down the barrier of
patient denial and gives the oncologist and community physician a
persuasive toehold."

"The community physidan ...
can be crudal in redudng
cancer mortality."
- Lewis Foxhall, M.D.,
co-medical director, M. D. Anderson's
Office of Referral Relations

"More and more patients are also
asking for genetic screening," Dr.
Bevers says, despite its high cost and .
their awareness that the results, even
though confidential, can raise new
fears and concerns when a genetic
marker linked to cancer is found.
"But because it's highly specialized
and involves DNA sequencing," Dr.
Bevers adds, "most national medical
associations recommend that the
community physician defer to
comprehensive cancer centers for
such screening. However, both the
patient and the community physician
can stay alert to any signs of genetic
predisposition to disease." Such a
predisposition would include a
strong family history of cancer,
such as breast, ovarian, colon, or
endometrial cancer.

M. D. Anderson Researchers

Study Children's School Lunch
At present, genetic screening can
be don e for colon, breast, ovarian,
and thyroid cancers. M. D. Anderson
offers th ese tests.
But Dr. Bevers points out that
community physicians can do a great
deal of screening in the office. What
they may not b e able to do (e.g.,
sigmoidoscopy) , they can order.
Results can th e n b e forwarded to
the oncologist.
"The community physician," says
Dr. Foxhall, "by providing preventive
clinical services to try to detect cancer
during its asymptomatic phase when
treatment can b e most effective,
can be crucial in reducing cancer
mortality."
For the busy community physician
who wants to improve his or her
screen ing program, whether for
those with a history of cancer or
without it, Dr. Foxhall recommends
a program developed by the U.S.
Public Health Service and now being
promoted by major medical associations called "Put Prevention Into
Practice," or PPIP.
Throu gh the Agency for Health
Care Policy and Research web site
(http://www.ahcpr.gov/ ppip),
community physicians and other
primary care providers have access to
useful patient h e alth questionnaires,
flow charts, patient education materials, reminder postcards, and recordkeeping tools meant to organize and
streamline screening in a busy practice. PPIP materials are also available .
through the Texas Department of
Public Health.
Thompson points out that patients,
too, can lead the early detection
effort. "Patients can keep educating
themselves and keep reminding their
own personal physicians of the need
for routine screening," she said. •
f oR MORE INFORMATION, contact the Cancer
Prevention Center at (713) 745-8040
or Dr. Foxhall at (713) 792-2202.
E-mail Dr. Bevers at tbevers@notes. mdacc.
tmc.edu and Dr. Foxhall at lfoxhall@
mdanderson. org.

Habits and Choices
ow scores by the nation's schoolchildren are sendi~g _rese~r~hers
scurrying. But this time zt zs to the
lunchroom, not the classroom.

L

Research shows that children consume fewer
than 2.5 servings of fruits and vegetables daily,
giving them a score below 50% on the test of e~ting
five servings per day. This dismal score so early m
life worries cancer prevention experts who say that
meeting the standard may reduce the risk of
Dr. Karen Cullen is
cancer by 30 % to 40 %.
leading a study of
To get answers, researchers are conducting a
schoolchildren 's
pilot study to determine what food choices chil?-ren
lunchtime eating habits.
make when selecting from an array of sweets, highfat snacks, fruits, and vegetables as lunch choices.
"If children are given freedom of choice in selecting food for lu?c~,
will their diets change for the worse?" asks Karen Cullen, DrPH, pnnnpal .
investigator for the two-year study funded by the Cancer Research Foundation
of America. Dr. Cullen is an assistant professor in the Department of Behavioral Science at The University of Texas M. D. Anderson Cancer Center.
__
As part of the study, 600 students at one mi~dle
-.i~school and four elementary schools in Texas City
are filling out daily food diaries for a week, recording for the researchers what they choose to eat for
lunch.
Recent studies show that the National School
Lunch Program meals provide a significant amount
Research shows that
children consume fewer of fruit and vegetables for third-grade children, says
Dr. Cullen. But no research to date has examined
than 2.5 servings of
what happens to children 's diets when they move
fruits and vegetables
into middle and junior high schools, where snack
daily, giving them a
bars offer competing foods, such as candy, chips,
score below 50 % on
and soft drinks.
the test of eating five
"We know that poor nutrition is a risk factor for
servings per day.
colorectal, prostate, and possibly breast cancers,"
says Dr. Bernard Levin, M. D. Anderson's vice
president for cancer prevention. "We ultimately want to _reduce the nu~~er
of cancers by seeing people begin in childhood to practice healthy nutntion
habits that last a lifetime," he said.
Investigators also will examine whether children chai:ige thei~ ~ating
habits over the course of the school year, perhaps choosmg nutntious foods
after the novelty of having less healthy foods available has worn off.
"This research will provide important information to enable us to develop and implement middle school nutrition behavior change programs
to influence children's choices of fruit, vegetables, and low-fat foods," says
Dr. Ellen Gritz, chair of the Department of Behavioral Science.
Results of this study may also enable schools to offer more healthful
lunch choices in a manner more acceptable to students, says Dr. Cullen.•
foR MORE INFORMATION,

contact Dr. Cullen at (713) 745-2847.
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M. D. Anderson Partidpates in
Multinational Breast Cancer Prevention
Trial of Tamoxifen and Raloxifene
by Alison Ruffin and Michael Courtney

he University of
Texas M. D. Anderson Cancer Center
is recruiting women
for a multinational study meant
to further define tamoxifen s role
in reducing breast cancer risk
by comparing it with raloxifene.
The study aims to determine
which is more effective in
reducing breast cancer risk
and which has fewer side
effects in postmenopausal
women at high risk for
breast cancer.

T

area women will have the chance to
participate in this important study."
Side effects are a major safety
interest because women who took
tamoxifen in the earlier study benefited from having fewer fractures
of the hip, wrist, and spine than did
controls, but they also experienced
increased risk of endometrial cancer,
deep vein thrombosis, pulmonary
embolism, and possibly stroke.

Tamoxifen, used as the
control in this National Cancer
Institute-supported trial, was
found last year in a doubleblind study of 13,000 pre- and
Researchers comparing the ability
postmenopausal women to
halve the women's risk of breast of tamoxifen and raloxifene to
prevent breast cancer intend to
cancer compared with that of
enroll 22, 000 postmenopausal
controls. Researchers cut the
women at increased risk.
trial short when tamoxifen 's
effectiveness became apparent.
The new trial, one of the
largest breast cancer prevention studies
"Tamoxifen is a medically proven
ever, expects to enroll 22,000 women at intervention but is not perfect," said
more than 400 centers across the
Dr. Bevers. "Women who are at inUnited States, Canada, and Puerto
creased risk of breast cancer need
Rico. Called the STAR trial (Study of
options for preventing this disease with
Tamoxifen And Raloxifene), the
a minimum of side effects, and STAR
research is part of the National Surgiis a concerted effort to find one."
cal Adjuvant Breast and Bowel Project.
Information about the safety of
M. D. Anderson plans to enroll 400
raloxifene is limited, according to
participants. Other study sites in Texas Dr. Bevers. Raloxifene was approved
include ones in Lufkin and El Paso.
in December 1997 by the U.S. Food
"We are excited about bringing
and Drug Administration (FDA) to
the STAR trial to the greater Houston
prevent osteoporosis and has been
metropolitan area," said Dr. Therese
in breast cancer clinical trials for
Bevers, principal investigator at
about five years. In a three-year
M. D. Anderson. "Women everystudy conducted by the University
where are at risk for breast cancer,
of California, San Francisco (UCSF),
and we are pleased that Houstonraloxifene decreased the risk of
4 I MD Anderson OncoLog

breast cancer in postmenopausal
women with osteoporosis by 76%.
Tamoxifen, approved by the FDA as
a breast can cer treatment for more
than 20 years, h as been in clinical
trials for about 30 years.
Women taking raloxifene in
studies of osteoporosis have had an
increased chance of deep vein thrombosis or pulmonary embolism similar
to the risk seen with tamoxifen. But
neither in these studies nor in the
UCSF study did raloxifene increase
the risk of endometrial cancer.
Women who participate in
STAR must be postmenopausal,
at least age 35, and have an
increased risk of breast cancer
as determined by their age,
family history of breast cancer,
personal m e dical history, age at
first m enstrual period, and age
at bir th of their first child.
Once a woman chooses
to participate, she will be
randomly assigned to receive
either 20 mg of tamoxifen or
60 mg of raloxifene daily for
five years an d will have regular
follow-up examinations, including m ammograms and gynecologic exams.
Tamoxifen 's manufacturer,
Zeneca Pharmaceuticals of
Wilmington , Delaware, and the
maker of raloxifene, Eli Lilly and
Company of Indianapolis, Indiana,
are providing drugs for the trial
without charge. •
FoR MORE INFORMATION about STAR visit
M. D. Anderson's web site at http://
www.mdanderson. org, the National
Surgical Adjuvant Breast and Bowel
Project web site at http://www. nsabp.
pitt. edu, or the National Cancer
Institute's clinical trials web site at http://
cancertrials. nci. nih.gov. Additional
information is also available by phone
from M. D. Anderson's STAR line at
(713) 792-8064 or from the Cancer
Information Service at (800) 4-CANCER.

Reduce Cancer Risk With
Regular Cancer Saeening
ou 've heard it many
times: early detection
of cancer saves lives.
By catching the disease
at an early stage, treatment is
more likely to be successful. But
while most of us are aware of the
value of regular cancer screening examinations, many of us
are confused about how often
we should get these checkups.

Y

Ivtcancer-related Checkup
In addition to age- and sexspecific cancer screening examinations done for cancers of the breast,
cervix, endometrium, prostate,
colon, and rectum, the American
Cancer Society recommends that
adults between the ages of 20 and 40
years have a cancer-related checkup
every three years. Once the person
reaches 40, the recommendation
is for a yearly checkup. Such an
examination should include health
counseling and, depending on the
person's age and sex, m ight include
examinations for cancers of the
thyroid, skin, oral cavity, lymph
nodes, testes, and ovaries.

I vt Tests for Women
M. D. Anderson Cancer Center
encourages women between the
ages of 20 and 39 years to perform
breast self-examinations each month
and to undergo a breast examination
by a health professional every one
to three years. For women 40 years
and older, experts add an annual
~ammogram and make the profess10nal breast examination an annual
requirement. The examination
performed in the clinic should
occur near the time of the mammogram. Throughout life, women are
encouraged to perform breast
self-examinations monthly.

M. D. Anderson also recommends
that all women have an annual pap
smear to check for cervical cancer.
Women who are at high risk for
cancer of the uterus should, according to the American Cancer Society,
have a sample of their endometrial
tissue examined when menopause
starts.

I ~ Tests for Men
Men age 50 to 70 years should
have a prostate-specific antigen blood
test and a digital rectal examination
by a health professional annually,
according to M. D. Anderson Cancer
Center recommendations. To detect
testicular cancer early, men should
perform a monthly testicular selfexamination to check for lumps or
other changes in their testicles.

I ~ Colon and Rectum
Examinations
M. D. Anderson recommends that
men and women who are 50 years or
older should have one of the following combinations of examinations:
• A yearly fecal occult blood test
( a sample of stool is examined for
blood) and a flexible sigmoidoscopy (an examination of the
rectum and lower colon with a
slender, lighted instrument)
every five years; or
• A colonoscopy (an examination
of the rectum and entire colon
with a lighted instrument) every
10 years; or
• A double-contrast barium enema
every 5 to 10 years.
A digital rectal examination
should be performed at the same
time as the sigmoidoscopy, colonoscopy, or double-contrast barium
enema. People who are at higherthan-average risk for colorectal
cancer should consult their doctor
about a recommended testing
schedule.

I ~ Skin and Oral Cavity
Examinations
Skin cancer is the most common
cancer, but most cases are highly
curable. Melanoma, skin cancer's
most serious form, is occurring more
frequently: its incidence rate has
more than doubled in the last two
decades. Experts recommend that
adults practice self-examination
regularly, and some say yearly examinations by a physician are necessary
if risk is higher than average.
Dentists and physicians should
check the oral cavity at regular
checkups for changes in the lining
of the oral cavity.
These various screening examinations can detect cancers of the breast,
cervix, colon, rectum, prostate, testes,
oral cavity, and skin at the earliest
and most treatable stages. These
cancers, according to the American
Cancer Society, account for about
half of all new cancer cases. The fiveyear relative survival rate for patients
with these cancers is about 81 %.
(A relative survival rate is the survival
rate of a group of patients with cancers
compared with the rate for a similar
group of persons in the general
population.) If all Americans participated in regular cancer screenings,
the ACS predicts, the rate could
increase to more than 95%.
That's a very good reason to make an
appointment right now for screening. •

For more information, contact
your physician or contact the
M. D. Anderson Information Line:

({) (800) 392-1611 within
the United States, or

({) (713) 792-6161 outside
the United States.
June 1999
© 1999 The University of Texas
M. D. Anderson Cancer Center

Nerve Grafting Attempts to Restore
Eredile Fundion After Prostatedomy
by Dawn Chalaire

espite advances
in surgi,cal
techniques and
postoperative
therapies, the
fact remains that for many men
with localized prostate cancer
the price of a potentially curative radical prostatectomy is
permanent sexual dysfunction.
"Sexual functioning is an important part of a man's life," said
Christopher G. Wood, M.D. , assistant
professor of urology and cancer
biology at The University of Texas
M. D. Anderson Cancer Center.
"To suggest to men that they need
to give that up in the name of cancer
control forces them to make a very
difficult and heartbreaking decision.
With the sural nerve graft, we're
offering an opportunity to maximize
cancer control and improve their
quality oflife."
Dr. Wood is the principal investigator in a phase I study to test the
safety and efficacy of using autologous sural nerve grafts to preserve
erectile function following radical
retropubic prostatectomy. Although
this particular study is being conducted exclusively at M. D. Anderson,
Baylor College of Medicine Assistant
Professor of Urology Edward D. Kim
is one of the study's coinvestigators.
Dr. Kim, who has a special interest
in erectile dysfunction and infertility,
and colleagues at Baylor are also
performing the procedure.
While there may be other causes
of erectile dysfunction following

Dr. Stephen Kroll (standing), professor
of plastic surgery, and Dr. Christopher
Wood, assistant professor of urology
and cancer biology, are collaborators
who are working to restore erectile
function in men after prostatectomy.
6 I MD Anderson OncoLog

radical prostatectomy, removal of the
cavernous nerves, located on either
side of the prostate gland, is the most
common cause of postoperative
impotence. The rate of impotence
following the removal of both
cavernous nerves is essentially 100%.
Depending on the stage, grade,
and location of the tumor, one or
both of the cavernous nerves are
sometimes left intact during prostatectomy. Between 40% and 60 % of
patients who undergo unilateral
nerve-sparing surgery retain the
ability to have spontaneous erections.
Some evidence suggests, though, that
leaving the cavernous nerves intact
increases a patient's risk of both
positive tumor margins and recurrence. The nerve bundles are a
common site of prostate cancer
and may even provide a pathway for
the cancer to spread outside the
prostate, according to Dr. Wood.

(

"By removing both nerves, you
definitely are going to improve
cancer control at the expense of
impotence after surgery, " Dr. Wood
said. "So the advantage of su ral nerve
grafting is to potentially address that
problem of impotence while still
optimizing cancer control. "
To be eligible, patie nts must be
candidates for radical prostatectomy
but have clinically localized disease
that requires bilateral removal of the
cavernous nerves. They must also
have normal erectile function b efore
surgery. Dr. Kim conducts p re- and
postoperative evaluations. Preoperative evaluation includes a physical
examination, completion of a questionnaire about the patient's sexual
history, and a determination of
baseline erectile functioning. T he
fairly common patient complain t
that penile length decreases following radical prostatectomy prompted
investigators to add evaluation of
pre- and postoperative erectile
length to the study's measures.
Other study coinvestigators at
M. D. Anderson include Richard

"The initial
results are quite
encouraging."
- Christopher G.
Wood, M.D.

i -

Babaian, M.D., professor of urology,
and Drs. Stephen Kroll and David
Chang, professors of plastic surgery.
One plastic surgeon and one urologist typically work together during
the three- to four-hour combined
prostatectomy and nerve-grafting
procedure.
The plastic surgeon harvests a
section of the sural nerve through
an incision in the back of the lower
right leg. Following the removal of
the prostate and surrounding nerve
bundles by the urologist, the plastic
surgeon cuts the sural n erve in half
and grafts it onto the preserved
stumps of each cavernous nerve.
Surgeons use loupes for magnification during suturing and must take
care to avoid tension on the nerve
grafts. The only permanent side
effect of the sural nerve harvest is
numbness in an area about the size
of a half dollar on the outside of
the ankle.
Four to six weeks after surgery,
Dr. Kim initiates erectile dysfunction
therapy. Research indicates that
beginning therapy as soon as possible
after surgery improves a patient's
chances of being able to have spontaneous erections. Therapy options
include sildenafil (Viagra) taken
orally; penile injections of papaverine, prostaglandin El, and phenotolamine (Trimix); a vacuum erection
device; and use of the m edicated
urethral system for erection (MUSE).
MUSE includes the insertion of a
pellet of prostaglandin into the
urethra through the tip of the penis.
Patients return at 3, 6, 12, and 24
months after surgery for assessment
of erectile function.
So far, 10 patients have undergone
prostatectomy with bilateral nerve
grafting at M. D. Anderson, where
the enrollment target is 30 patients.
None of those patients have completed the 14 months of follow-up
investigators think is necessary to
determine if the procedure has been
successful, but some patients have
reported by telephone that they are
having erections. At Baylor, Dr. Kim's
initial results indicate a success rate
of about 60% among the 15 patients
who have undergone the surgery
and passed the 14-month postoperative evaluation point.

"One of the things that should
be emphasized is that this is a research study. While the initial results
are quite good, I do believe that it's
going to be very much surgeon
dependent, on the part of both the
plastic surgeon and the urologist
involved in the case," Dr. Wood said.
The concept of using autologous
nerve grafting to maintain erectile
function is not new. In a 1991 laboratory study, the genitofemoral nerve
was used to replace the cavernous
nerves following radical retropubic
prostatectomy in rats, resulting in a
significant return of erectile function.
But a subsequent attempt to use
genitofemoral nerve grafting in
humans was not successful, the procedure became controversial, and many
urologists abandoned the idea.
"This is not something that everyone has signed on to," Dr. Wood said.
"Actually, most people have not, but
our approach to it has been: it's an
unknown, the initial results are quite
encouraging, and it's something we
should evaluate."
One of the arguments against the
grafting centers around the differences in impulse conduction believed
to occur when the sural nerve, which
is myelinated, is used to replace the
unmyelinated cavernous nerve. Dr.
Wood points out that grafted nerves
eventually become unmyelinated and
serve as a scaffold, rather than a
bridge, for nerve fibers at one end
to grow back to the other side.
According to Dr. Kroll, it is not
that nerve grafting is inappropriate,
it is that grafting is complex. He said
the difficulty involved with attempting a nerve-grafting procedure so
deep within the pelvic cavity might
explain why the technique has not
been successful before, even though
the concept behind it is sound.
"Nerve grafting is a well-accepted
procedure that has been done for
many years with a high rate of
success," he said. "It's not a new
idea to repair nerves." He said the
procedure is 'Just a logical extension
of traditional plastic surgery to a
new area." •
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'Guide for
Referring
Physicians

1999-2000
A 124-page
guide to the
cancer center's
faculty and
services 1s
now available.
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Guide for
Referring Physicians
1999-2000

To receive
your free copy,
complete and
send the form below to Lewis E.
Foxhall, M.D., Office of Referral
Relations-Box 223, M. D. Anderson
Cancer Center, 1515 Holcombe
Boulevard, Houston, Texas 77030,
or Jax it to (713) 794-4685. You may
also call (800) 250-0502 or (713)
794-5005 to request a copy.

□

Please send me a free copy of

Guide for Referring
Physicians 1999-2000.

NAME

ADDRESS

CI'IY, STATE, ZIP

AREA CODE AND PHONE NUMBER

contact Dr. Kroll
at (713) 794-1247 or Dr. Wood at (713)
792-3250.

FoR MORE INFORMATION,

E-MAIL ADDRESS

L ____________
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Staff Publications
in June
Below is a partial list of staff
publications appearing this month.
Aboul- a r R et al. Comparison
of touch imprints with
aspirate smears for evaluating bone marrow specimens.
Am] Clin Pathol
1999;1 ll (6):753-8.
Allgayer H et al. Transcriptional
induction of the urokina e
receptor gene by a con titutively active Src. Requirement of an upstream motif
(-152 / -135) bound with Spl.
]Biol Chem
l 999;274(26): 18428-37.
Anderlini P et al. Allogeneic
blood progenitor cell
collection in normal donor
after mobilization with
filgra tim: the M.D.
Ander on Cancer Center
experience. Transfusion
1999;39(6) :555-60.
Beaupre DM et al. Autocrine
inter! ukin-1-beta production in leukemia: evidence
for the involvement of
mutated RAS. Cancer Res
1999;59 ( 12) :2971-80.
Davies MA et al. Regulation of
Akt/PKB activity, cellular
growth, and apoptosis in
prostate carcinoma cells by
MMAC/ PTEN. Cancer Res
1999;59 ( 11) :2551-6.
Esmaeli-Gutstein B, Wmkelman JZ.
Uveitis associated with varicella
virus vaccine. Am] Dphthalmol
1999;127(6) :733-4.
Kardon R et al. Bacterial
conjunctivitis in Mucl null
mice. Invest Ophthalmol Vis
Sci 1999;40(7):1328-35.
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Levy DA et al. Tran rectal
ultra ound-guided
intrapro tatic injection of
absolute ethanol with and
without carmu tine: a
fea ibility tudy in th canine
model. Urology
1999;53 (6): 1245-51.
Mitchell DL et.al. Effects of
chronic low-dose ultraviolet B
radiation on D A damage and
repair in mou e kin. Cancer
Res 1999;59 ( 12) :2875-84.
MolldremJJ et al. A PRl-human
leukocyte antigen-A2
tetramer can be u ed to
i olate low-frequency
cytotoxic T lymphocyte from
healthy donors that electively lyse chronic myelogenou leukemia. Cancer Res
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